Literature DB >> 16096810

Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population.

M G Marrosu1, E Cocco, G Costa, M R Murru, C Mancosu, R Murru, M Lai, C Sardu, P Contu.   

Abstract

We examined the influence of alleles at the HLA loci, previously found to be associated with multiple sclerosis (MS) in Sardinia, on the clinical course of the disease in 835 relapsing (R) and 100 primary progressive (PP) patients. Multivariate analysis was carried out on predisposing 0301 or non-associated DPB1 alleles, susceptible or non-associated DRB1-DQB1 haplotypes, both predisposing and non-predisposing, and negatively and non-negatively associated D6S1683 alleles, taking interaction between them into account. Intra-patient analysis showed that the presence of the susceptible or protective D6S1683 allele interacting with predisposing DP 0301 modulated risk of PP disease. These findings suggest that a locus telomeric to HLA class I exerts an effect on alleles at the DPB1 locus in modulating disease course.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096810     DOI: 10.1007/s00415-005-0957-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

1.  The distribution of HLA class II haplotypes reveals that the Sardinian population is genetically differentiated from the other Caucasian populations.

Authors:  R Lampis; L Morelli; S De Virgiliis; M Congia; F Cucca
Journal:  Tissue Antigens       Date:  2000-12

2.  A genome-wide screen for linkage disequilibrium in Sardinian multiple sclerosis.

Authors:  Francesca Coraddu; Marina Lai; Cristina Mancosu; Eleonora Cocco; Stephen Sawcer; Efrosini Setakis; Alastair Compston; Maria Giovanna Marrosu
Journal:  J Neuroimmunol       Date:  2003-10       Impact factor: 3.478

3.  Updated results of the United Kingdom linkage-based genome screen in multiple sclerosis.

Authors:  A E Hensiek; R Roxburgh; B Smilie; F Coraddu; E Akesson; P Holmans; S J Sawcer; D A S Compston
Journal:  J Neuroimmunol       Date:  2003-10       Impact factor: 3.478

4.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

5.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

Review 6.  The pathology of primary progressive multiple sclerosis.

Authors:  W Brück; C Lucchinetti; H Lassmann
Journal:  Mult Scler       Date:  2002-04       Impact factor: 6.312

7.  HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies.

Authors:  K Yamasaki; I Horiuchi; M Minohara; Y Kawano; Y Ohyagi; T Yamada; F Mihara; H Ito; Y Nishimura; J Kira
Journal:  Brain       Date:  1999-09       Impact factor: 13.501

8.  Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study.

Authors:  B G Weinshenker; P Santrach; A S Bissonet; S K McDonnell; D Schaid; S B Moore; M Rodriguez
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

9.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis.

Authors:  A J Thompson; A G Kermode; D Wicks; D G MacManus; B E Kendall; D P Kingsley; W I McDonald
Journal:  Ann Neurol       Date:  1991-01       Impact factor: 10.422

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  5 in total

1.  Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients.

Authors:  Justin P Rubio; Melanie Bahlo; Jim Stankovich; Rachel K Burfoot; Laura J Johnson; Stewart Huxtable; Helmut Butzkueven; Ling Lin; Bruce V Taylor; Terence P Speed; Trevor J Kilpatrick; Emmanuel Mignot; Simon J Foote
Journal:  Immunogenetics       Date:  2007-01-26       Impact factor: 2.846

Review 2.  The immunogenetics of multiple sclerosis: A comprehensive review.

Authors:  Jill A Hollenbach; Jorge R Oksenberg
Journal:  J Autoimmun       Date:  2015-07-02       Impact factor: 7.094

3.  Analysis of HLA DR2&DQ6 (DRB1*1501, DQA1*0102, DQB1*0602) haplotypes in Iranian patients with multiple sclerosis.

Authors:  Mojdeh Ghabaee; Asghar Bayati; Shahla Amri Saroukolaei; Mohamad Ali Sahraian; Mohammad Hosein Sanaati; Parisa Karimi; Massoud Houshmand; Homa Sadeghian; Leila Hashemi Chelavi
Journal:  Cell Mol Neurobiol       Date:  2008-08-26       Impact factor: 5.046

4.  A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosis.

Authors:  Judith Field; Sharon R Browning; Laura J Johnson; Patrick Danoy; Michael D Varney; Brian D Tait; Kaushal S Gandhi; Jac C Charlesworth; Robert N Heard; Graeme J Stewart; Trevor J Kilpatrick; Simon J Foote; Melanie Bahlo; Helmut Butzkueven; James Wiley; David R Booth; Bruce V Taylor; Matthew A Brown; Justin P Rubio; Jim Stankovich
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

5.  Class II HLA interactions modulate genetic risk for multiple sclerosis.

Authors:  Loukas Moutsianas; Luke Jostins; Ashley H Beecham; Alexander T Dilthey; Dionysia K Xifara; Maria Ban; Tejas S Shah; Nikolaos A Patsopoulos; Lars Alfredsson; Carl A Anderson; Katherine E Attfield; Sergio E Baranzini; Jeffrey Barrett; Thomas M C Binder; David Booth; Dorothea Buck; Elisabeth G Celius; Chris Cotsapas; Sandra D'Alfonso; Calliope A Dendrou; Peter Donnelly; Bénédicte Dubois; Bertrand Fontaine; Lars Fugger; An Goris; Pierre-Antoine Gourraud; Christiane Graetz; Bernhard Hemmer; Jan Hillert; Ingrid Kockum; Stephen Leslie; Christina M Lill; Filippo Martinelli-Boneschi; Jorge R Oksenberg; Tomas Olsson; Annette Oturai; Janna Saarela; Helle Bach Søndergaard; Anne Spurkland; Bruce Taylor; Juliane Winkelmann; Frauke Zipp; Jonathan L Haines; Margaret A Pericak-Vance; Chris C A Spencer; Graeme Stewart; David A Hafler; Adrian J Ivinson; Hanne F Harbo; Stephen L Hauser; Philip L De Jager; Alastair Compston; Jacob L McCauley; Stephen Sawcer; Gil McVean
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.